Preparation and application of absorbable stent for human alveolar bone reconstruction

Polylactic acid and hydroxyapatite were resolved by using porous structures and zinc oxide nanowires of bioactive glass in alveolar bone scaffolds, as well as the combination of chitosan, icariin and echino collagen in the combination of hydroxyapatite. The problem of insufficient toughness and hardness has achieved stable repair and antibacterial and anti-inflammatory effects of alveolar bone.

CN119055831AInactive Publication Date: 2024-12-03HOSPITAL OF STOMATOLOGY GUANGZHOU MEDICAL UNIVERSITY (YANGCHENG HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY)
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411217503.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Polylactic acid has low toughness and high brittleness, which limits its application on absorbable stents; hydroxyapatite has low hardness and high brittleness, which is prone to collapse, resulting in unstable alveolar bone repair effect.

Method used

Hydroxyapatite mixed with bioactive glass to form a porous structure and form zinc oxide nanowires in its pores to improve mechanical strength; at the same time, the cross-linking network structure of chitosan and icariin and fish scale collagen The grafting reaction with chlorogenic acid enhances the adsorption properties and antibacterial properties of the material, and enhances the mechanical strength of polylactic acid by copolymerizing lactide with 2-methacryloyloxyethylphosphate choline.

Benefits of technology

It improves the mechanical strength and biocompatibility of the alveolar bone stent, extends the drug delayed release time, promotes the repair of alveolar bone and bone regeneration, and enhances antibacterial and anti-inflammatory properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005021973030000151
    Figure BDA0005021973030000151
Patent Text Reader

Abstract

The invention discloses preparation and application of an absorbable stent for human alveolar bone reconstruction, and belongs to the technical field of biomedical materials.The preparation method comprises the following steps that alpha-tricalcium phosphate, modified polylactic acid, composite hydroxyapatite and nanometer magnesium oxide are mixed and subjected to ball milling for three times, then ball milling and materials are separated through a screen, and a mixture subjected to ball milling treatment is obtained; and carrying out melt blending on the mixture subjected to ball milling treatment, carrying out tabletting treatment, cooling to room temperature, and carrying out model cutting and printing through a CAD / CAM technology to obtain the absorbable stent. The zinc oxide nanowire is used as a supporting framework of the porous hydroxyapatite, so that the mechanical strength of the porous hydroxyapatite is improved, and the porous hydroxyapatite is prevented from being easily collapsed under an occlusal force; the chlorogenic acid is grafted on the fish scale collagen, so that the molecular weight of the chlorogenic acid is increased, and easy migration and precipitation of the chlorogenic acid are avoided; the modified polylactic acid and the composite antibacterial material are combined through chemical bonds to form a porous net-shaped spongy structure, so that the mechanical strength of the absorbable stent is enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomedical materials, in particular to the preparation and application of an absorbable scaffold for human alveolar bone reconstruction. Background Art

[0002] Alveolar ridge hypoplasia, severe periodontal disease, tumors or trauma can cause alveolar bone atrophy, alveolar bone defects and other problems. The premise for successful implantation is to ensure that there is enough alveolar bone and the implant will not be infected after bone grafting. The commonly used methods for repairing alveolar bone in clinical practice are autologous bone transplantation, allogeneic bone transplantation and bone tissue engineering materials. Bone tissue engineering materials such as polylactic acid and poly D, L-lactic acid are considered to be polymers with good biocompatibility and degradability. They are mixed with calcium triphosphate and hydroxyapatite as alveolar bone absorbable scaffolds. In order to improve their osteoconductivity, they are often prepared into porous structures, so that the living bone can be regenerated after a period of time, and the bioabsorbable scaffold material can be degraded and disappear, leaving the regenerated bone structure.

[0003] Polylactic acid, as an absorbable scaffold matrix for human alveolar bone reconstruction, has good biocompatibility and in vivo degradability, but polylactic acid has low toughness and high brittleness, which limits its application in absorbable scaffolds; hydroxyapatite is the main inorganic component in human bones, has good biocompatibility in the body, and can promote the growth of bones and teeth, thereby accelerating the repair process of alveolar bone, but pure hydroxyapatite has low hardness, high brittleness, and is prone to collapse, resulting in unstable effects in repairing alveolar bone thickness and alveolar ridge height. Summary of the invention

[0004] The purpose of the present invention is to provide the preparation and application of an absorbable scaffold for human alveolar bone reconstruction: hydroxyapatite and bioactive glass are mixed and sintered, and then mixed with a zinc precursor solution and a zinc ammine complex solution, and heated to react, so as to form randomly distributed zinc oxide nanowires in the porous hydroxyapatite pores, and the formed zinc oxide nanowires serve as the supporting skeleton of the porous hydroxyapatite, thereby improving the mechanical strength of the porous hydroxyapatite and avoiding easy collapse under the action of the bite force; modified hydroxyapatite, icariin and chitosan are mixed, stirred and reacted to obtain a scaffold, wherein the chitosan forms a cross-linked network structure on the surface of the composite hydroxyapatite, and the modified hydroxyapatite has excellent adsorption performance, thereby achieving the adsorption of icariin. The adsorption of icariin increases the sustained-release time of icariin and maximizes the effect of icariin; fish scale collagen reacts with chlorogenic acid, and chlorogenic acid is grafted onto fish scale collagen to increase the molecular weight of chlorogenic acid and avoid the migration and precipitation of chlorogenic acid in the polylactic acid absorbable scaffold; lactide is copolymerized with 2-methacryloyloxyethyl phosphorylcholine through hydroxyethyl acrylate and then mixed with the composite antibacterial material. The ester group, carboxyl group and hydroxyl group contained in the polylactic acid carrying phosphorylcholine group can be combined with the hydroxyl, amino and carboxyl groups in the composite antibacterial material through chemical bonds, and are cross-linked to form a porous mesh and sponge-like structure, thereby enhancing the mechanical strength of the polylactic acid matrix of the absorbable scaffold.

[0005] The technical problems to be solved by the present invention are as follows: polylactic acid has low toughness and high brittleness, which limits its application in absorbable scaffolds; hydroxyapatite is the main inorganic component in human bones, has good biocompatibility in the body, can promote the growth of bones and teeth, and thus accelerate the repair process of alveolar bone, but pure hydroxyapatite has low hardness, high brittleness, and is prone to collapse, resulting in unstable effects in repairing alveolar bone thickness and alveolar ridge height.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] The method for preparing an absorbable scaffold for human alveolar bone reconstruction comprises the following steps:

[0008] S1. α-tricalcium phosphate, modified polylactic acid, composite hydroxyapatite and nano-magnesium oxide are mixed, ball-milled three times, and then the ball-milled and material are separated through a sieve to obtain a ball-milled mixture.

[0009] Furthermore, the mass ratio of α-tricalcium phosphate, modified polylactic acid, composite hydroxyapatite, and nano-magnesium oxide is (0.8-1.2):(0.6-0.8):(0.1-0.2):(0.02-0.04).

[0010] Furthermore, the particle size of nano magnesium oxide is 40-60nm.

[0011] More preferably, the particle size of the nano magnesium oxide is 50 nm.

[0012] Furthermore, the ball milling conditions are as follows: the ratio of the number of 3 mm and 5 mm oxide balls is 4:1, the ball milling speed is 280-320 r / min, the ball milling process is forward for 25-35 min, stopped for 8-12 min, and reversed for 25-35 min.

[0013] Further preferably, the ball milling conditions are as follows: the ratio of the number of 3 mm and 5 mm oxide balls is 4:1, the ball milling speed is 300 r / min, the ball milling process is forward for 30 min, stopped for 10 min in the middle, and reversed for 30 min.

[0014] Furthermore, the mesh size is 6-7 mm.

[0015] S2. The ball-milled mixture is melt-blended, and then tableted, cooled to room temperature, and modeled and printed using CAD / CAM technology to obtain an absorbable scaffold.

[0016] Furthermore, the tableting pressure is 6-8 tons, and the tableting holding time is 0.5-1.5 minutes.

[0017] Further preferably, the tableting pressure is 7 tons and the tableting holding time is 1 min.

[0018] Furthermore, the melt blending temperature is 150-160° C., the melt blending time is 2-7 min, and the rotation speed is 60-70 rpm.

[0019] More preferably, the melt blending temperature is 155° C., the melt blending time is 5 min, and the rotation speed is 65 rpm.

[0020] Furthermore, the CAD / CAM technology model designs a wire diameter of 450-550um and an aperture of 200-300um.

[0021] Furthermore, the printing parameters are as follows: layer height 0.1 mm, filling rate 100%, printing rate 30 mm / s, printing temperature 185 °C, platform temperature 45 °C, and printing nozzle 0.1 mm.

[0022] Further preferably, the CAD / CAM technical model designs a line diameter of 500um and a hole diameter of 250um.

[0023] Furthermore, the composite hydroxyapatite is prepared by mixing modified hydroxyapatite, icariin and chitosan, and stirring the mixture for reaction, and is specifically prepared by the following steps:

[0024] Add icariin to anhydrous ethanol and stir evenly, add chitosan and 2% acetic acid solution by mass and stir evenly, add modified hydroxyapatite, react with stirring for 30 minutes, stand at 4°C for 6 hours, and freeze at -10°C for 3 hours to obtain composite hydroxyapatite.

[0025] Among them, chitosan reacts with modified hydroxyapatite to form a cross-linked network structure on the surface of composite hydroxyapatite, and the modified hydroxyapatite porous structure has excellent adsorption properties. The zinc oxide nanowires in its pores are positively charged, and icariin contains a large number of hydroxyl structures and is negatively charged. Through adsorption and electrostatic bonding, icariin is embedded in the cross-linked network on the surface of hydroxyapatite, achieving the adsorption of icariin, increasing the sustained release time of icariin, exerting the maximum effect of icariin, improving the bone induction activity and the regeneration rate of bone tissue at the implantation site, thereby promoting the repair effect of alveolar bone.

[0026] Furthermore, the dosage ratio of icariin, anhydrous ethanol, chitosan, acetic acid solution, and modified hydroxyapatite is (2-3) g: (8-12) mL: (3-3.4) g: (15-25) mL: (5-6) g.

[0027] Furthermore, the modified hydroxyapatite is prepared by mixing hydroxyapatite and bioactive glass, sintering the mixture, and then mixing the mixture with a zinc precursor solution and a zinc ammine complex solution, and heating the mixture for reaction.

[0028] Furthermore, the particle size of hydroxyapatite is 0.1-2 μm.

[0029] Furthermore, the zinc precursor solution is prepared by mixing zinc acetate, polyethylene glycol 600 and deionized water in a dosage ratio of (3.5-4) g:(10-20) g:(40-50) mL.

[0030] Furthermore, the zinc ammonia complex solution is prepared by mixing zinc nitrate and ammonia water in a dosage ratio of (1.6-2) g:(10-12) mL.

[0031] Furthermore, the sintering temperature is 600-800° C., and the sintering time is 2-4 hours.

[0032] Further, the modified hydroxyapatite is specifically prepared by the following steps:

[0033] A1. Mix hydroxyapatite and bioactive glass, place them in ethanol, stir them for 24 hours to ensure homogenization, heat them to 100°C, dry them for 2 hours, place them in a sintering furnace, sinter them at 700°C for 3 hours, and cool them to room temperature to obtain porous hydroxyapatite.

[0034] Among them, hydroxyapatite and bioactive glass are mixed and heat treated at 700°C for 3 hours. The bioactive glass undergoes viscous flow and covers the surface of hydroxyapatite particles, increasing the bioactivity of hydroxyapatite. The hydroxyl groups in hydroxyapatite and the silicon-oxygen bonds in the bioactive glass are combined through chemical bonds, and the organic components in the bioactive glass are decomposed to form porous hydroxyapatite with interconnected pores. Its larger porosity and specific surface area are conducive to the adsorption of icariin and promote the proliferation of osteoblasts.

[0035] Furthermore, the mass ratio of hydroxyapatite to bioactive glass is (2-4) g:(0.5-1.5).

[0036] Furthermore, the pore size of the porous hydroxyapatite is 1-2 μm.

[0037] A2. Add porous hydroxyapatite to the zinc precursor solution, stir for 3 hours, dry at 100°C for 1 hour to remove most of the water, place it in a muffle furnace and heat it at 200°C for 1 hour, raise the temperature to 650°C and maintain it for another 20 minutes, cool to room temperature, add zinc ammonia complex solution, stir for 6 hours, react at 90°C for 6 hours, raise the temperature to 100°C, continue to react for 12 hours, cool to room temperature, wash with deionized water 5 times, and dry in a 60°C oven for 20 minutes to obtain modified hydroxyapatite.

[0038] Among them, porous hydroxyapatite contains a pore structure with a pore size of 1-2μm and a large specific surface area, which can adsorb the zinc precursor solution on the surface and pores of the porous hydroxyapatite. High-temperature treatment at 650°C for 20 minutes can completely decompose zinc acetate to form zinc oxide seeds that are firmly attached to the pore walls of the porous hydroxyapatite.

[0039] Further, it is mixed with a zinc ammine complex solution, and the zinc ammine complex solution can enter the pores of the porous hydroxyapatite containing zinc oxide seeds. It is hydrothermally treated at 90-100°C, so that the zinc ammine complex solution decomposes to form zinc hydroxide deposited on the porous hydroxyapatite. The hydrothermal reaction is continued, the zinc hydroxide decomposes, and the formed zinc oxide can grow in combination with the porous hydroxyapatite zinc oxide seeds to form zinc oxide nanowires, thereby forming zinc oxide nanowires in the pores of the porous hydroxyapatite, which serve as a supporting skeleton of the porous hydroxyapatite, thereby improving the mechanical strength of the porous hydroxyapatite, and avoiding easy collapse under the action of the bite force, resulting in unstable effects in repairing the thickness of the alveolar bone and the height of the alveolar ridge.

[0040] Furthermore, the amount ratio of porous hydroxyapatite, zinc precursor solution, and zinc ammine complex solution is (3-4) g: (8-12) mL: (5-6) mL.

[0041] Furthermore, the modified polylactic acid is prepared by copolymerizing lactide with hydroxyethyl acrylate and 2-methacryloyloxyethyl phosphorylcholine, and then mixing with a composite antibacterial material.

[0042] Furthermore, the lactide is selected from L-lactide or D-lactide.

[0043] Further, the modified polylactic acid is specifically prepared by the following steps:

[0044] B1. Lactide, erythrotetracycline and hydroxyethyl acrylate are mixed, stirred and reacted at 150°C for 10 minutes, cooled to room temperature, washed with deionized water three times, dried in an oven at 60°C for 10 minutes, added to ethanol, stirred evenly, azobisisobutyronitrile and 2-methacryloyloxyethyl phosphorylcholine were added, reacted at 60°C for 30 minutes, filtered, stirred at 85°C until the organic solvent evaporated, washed with deionized water three times, and dried in an oven at 60°C for 10 minutes to obtain a composite.

[0045] Among them, under the action of the initiator erythritol, the hydroxyl group of hydroxyethyl acrylate undergoes a ring-opening reaction with lactide to form polylactic acid, so that hydroxyethyl acrylate is grafted on the molecular weight of polylactic acid and carries reactive double bonds.

[0046] Furthermore, at 60°C, under the action of the initiator azobisisobutyronitrile, the polylactic acid grafted with hydroxyethyl acrylate causes the double bonds of 2-methacryloyloxyethyl phosphorylcholine and the polylactic acid grafted with hydroxyethyl acrylate to copolymerize, so that the polylactic acid carries the phosphorylcholine group, enhances the anti-protein adsorption ability, and further improves the biocompatibility, so that the polylactic acid absorbable scaffold is better integrated with the alveolar bone, which is beneficial to the regeneration of the alveolar bone.

[0047] Furthermore, the mass ratio of lactide, hydroxyethyl acrylate and 2-methacryloyloxyethyl phosphorylcholine is (6-7):(3-4):(1-2).

[0048] B2. Add the composite and composite antibacterial material into deionized water, stir evenly, add sodium hydroxide, stir in a 50°C water bath for 3 hours. After the reaction is completed, filter, wash with deionized water 3 times, and freeze-dry at -10°C to obtain modified polylactic acid.

[0049] Among them, the ester group, carboxyl group and hydroxyl group contained in the complex carrying the phosphorylcholine group can be combined with the hydroxyl group, amino group and carboxyl group of the fish scale collagen in the composite antibacterial material through chemical bonds, and cross-linked into a porous network and sponge-like structure, thereby enhancing the mechanical strength of the absorbable scaffold matrix polylactic acid. Its porous structure provides space for bone growth and vascular tissue growth.

[0050] Furthermore, the usage ratio of the composite, the composite antibacterial material, the deionized water and the sodium hydroxide is (4-6) g:(1-2) g:(15-25) mL:(0.1-0.3) g.

[0051] Furthermore, the composite antibacterial material is prepared by reacting fish scale collagen with chlorogenic acid; specifically, the composite antibacterial material is prepared by the following steps:

[0052] The fish scale collagen and chlorogenic acid were added to deionized water and stirred evenly, and 85% by mass phosphoric acid was added. After stirring and reacting at 55°C for 30 minutes, the mixture was filtered, washed with deionized water for 3 times, and freeze-dried at -10°C to obtain a composite antibacterial material.

[0053] Among them, at 55°C, phosphoric acid acts as a catalyst, allowing the amino and carboxyl groups in fish scale collagen to combine with the phenolic hydroxyl and carboxyl groups in chlorogenic acid through chemical bonds, so that chlorogenic acid is grafted onto fish scale collagen, increasing the molecular weight of chlorogenic acid and preventing chlorogenic acid from easily migrating and precipitating in the polylactic acid absorbable scaffold, resulting in reduced antibacterial properties and affecting the repair of alveolar bone.

[0054] Furthermore, the mass ratio of fish scale collagen, chlorogenic acid and phosphoric acid is (2-3):(2-4):(0.1-0.3).

[0055] Furthermore, fish scale collagen is specifically prepared by the following steps: washing fish scales with deionized water for 5 times, grinding in a grinder to obtain fish scale powder, adding the fish scale powder to a 6% by mass citric acid solution, soaking for 4 hours for decalcification, filtering, washing with deionized water until the washing solution is neutral, adding to 0.5 mol / L acetic acid, stirring, adding pepsin, enzymolysis for 48 hours, collecting the supernatant by filtration, adding sodium chloride to the above supernatant, stirring, salting out overnight at 4°C, centrifuging at a rate of 10000r / min for 30 minutes, dialyzing with 0.1 mol / L acetic acid for 24 hours, and obtaining fish scale collagen.

[0056] Furthermore, the dosage ratio of fish scale powder, citric acid solution, acetic acid, pepsin and sodium chloride is (0.5-1.5) g: (10-20) mL: (10-20) mL: (0.01-0.03) g: (0.1-0.3) g.

[0057] Compared with the prior art, the present invention has the following beneficial effects:

[0058] (1) In the technical solution of the present invention, the bioactive glass has good biological activity, bone conduction and bone stimulation, and the β-tricalcium phosphate contained in it is similar to the inorganic components of human bones, and can adsorb bone induction factors such as bone morphogenetic protein and epidermal growth factor very well, thereby promoting bone growth and regeneration, and is beneficial to the formation of alveolar bone; hydroxyapatite and bioactive glass form porous hydroxyapatite with interconnected pores, and its large porosity and specific surface area are beneficial to the adsorption of icariin and promote the proliferation of osteoblasts.

[0059] (2) In the technical scheme of the present invention, randomly distributed zinc oxide nanowires are formed in the pores of porous hydroxyapatite. The formed zinc oxide nanowires serve as the supporting skeleton of the porous hydroxyapatite, thereby improving the mechanical strength of the porous hydroxyapatite and avoiding collapse under the action of bite force, resulting in unstable effects in repairing the thickness of the alveolar bone and the height of the alveolar ridge. The zinc oxide nanowires refine the pore size of the porous hydroxyapatite, improve the porosity, increase the loading amount and adsorption capacity of icariin, and improve the sustained release time. In addition, the higher pore structure provides space for bone growth and vascular tissue growth, promotes the proliferation of osteoblasts, and the formed zinc oxide nanowires have good antibacterial properties, and can also stimulate the proliferation and migration of vascular endothelial cells, promote the formation of vascular networks, and provide sufficient nutrition and oxygen supply for alveolar bone repair.

[0060] (3) In the technical scheme of the present invention, icariin is a plant flavonoid glycoside compound, which, as a bone-inducing active factor, can promote the proliferation of osteoblasts and promote the metabolism and differentiation of osteoblasts; chitosan reacts with modified hydroxyapatite to form a cross-linked network structure on the surface of modified hydroxyapatite, and the modified hydroxyapatite porous structure has excellent adsorption performance, and the zinc oxide nanowires in its pores are positively charged. Icariin contains a large number of hydroxyl structures and is negatively charged. Through adsorption and electrostatic bonding, icariin is embedded in the cross-linked network on the surface of hydroxyapatite, thereby achieving adsorption of icariin, increasing the sustained release time of icariin, exerting the maximum effect of icariin, improving the bone-inducing activity and the regeneration rate of bone tissue at the implantation site, thereby promoting the repair effect of alveolar bone; after hydroxyapatite is implanted in the body, calcium and phosphorus elements will be released and absorbed by body tissues, promoting the growth of bones and teeth, and accelerating the repair process of alveolar bone.

[0061] (4) In the technical scheme of the present invention, chlorogenic acid can effectively inhibit oxidative free radicals and has high anti-inflammatory and antibacterial activity. Therefore, it has anti-inflammatory and antibacterial activity on alveolar bone. Chlorogenic acid is grafted on fish scale collagen to increase the molecular weight of chlorogenic acid, thereby preventing chlorogenic acid from easily migrating and precipitating in the polylactic acid absorbable scaffold, resulting in reduced antibacterial performance and affecting the repair of alveolar bone. Fish scale collagen contains a large number of oxygen-containing functional groups, has excellent cell adhesion and biocompatibility, and can be combined with the absorbable scaffold matrix polylactic acid, so that the antibacterial active material is better combined with polylactic acid. In addition, fish scale collagen has a pro-proliferation and pro-differentiation effect on bone cells, has good osteogenesis, and thus promotes the growth of bones and teeth and accelerates the repair process of alveolar bone.

[0062] (5) In the technical scheme of the present invention, lactide is copolymerized with 2-methacryloyloxyethyl phosphorylcholine through hydroxyethyl acrylate, so that the molecular weight of polylactic acid carries phosphorylcholine groups, which enhances the ability to resist protein adsorption and further improves the biocompatibility, so that the polylactic acid absorbable scaffold is better combined with the alveolar bone, which is beneficial to the regeneration of the alveolar bone; the polylactic acid carrying phosphorylcholine groups is mixed with the composite antibacterial material, and the ester group, carboxyl group and hydroxyl group contained in the polylactic acid carrying phosphorylcholine groups can be combined with the hydroxyl group, amino group and carboxyl group in the composite antibacterial material through chemical bonds, and cross-linked to form a porous network and sponge structure, thereby enhancing the mechanical strength of the absorbable scaffold matrix polylactic acid, and its porous structure provides space for bone growth and vascular tissue growth. In addition, the fish scale collagen in the modified polylactic acid can be complexed with the calcium ions in the composite hydroxyapatite, thereby enhancing the spatial structure of the porous absorbable scaffold and enhancing the mechanical strength of the absorbable scaffold. DETAILED DESCRIPTION

[0063] The technical solutions in the embodiments of the present invention are described clearly and completely. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0064] The raw materials used in the embodiments of the present invention are as follows:

[0065] The bioactive glass was purchased from Beijing Organic Chemical Plant, and its SiO2 content was 43-44.5%, CaO content was 45-46.5%, Na2O content was 4-6%, and P2O5 content was 4.0-6.0%.

[0066] The particle size of hydroxyapatite is 0.1-2 μm.

[0067] The particle size of nano magnesium oxide is 50nm.

[0068] Fish scale collagen is specifically prepared by the following steps:

[0069] The fish scales were washed with deionized water for 5 times, ground in a grinder to obtain fish scale powder, 1 g of the fish scale powder was added to 15 mL of a 6% by mass citric acid solution, soaked for 4 hours for decalcification, filtered, washed with deionized water until the washing solution was neutral, added to 15 mL of 0.5 mol / L acetic acid, stirred, 0.02 g of pepsin was added, and after enzymatic hydrolysis for 48 hours, the supernatant was collected by filtration, 0.2 g of sodium chloride was added to the supernatant, stirred, salted out at 4°C overnight, centrifuged at 10,000 r / min for 30 minutes, dialyzed with 0.1 mol / L acetic acid for 24 hours, and fish scale collagen was obtained.

[0070] Example 1

[0071] The composite hydroxyapatite is specifically prepared by the following steps:

[0072] A1. Mix 3 g of hydroxyapatite and 1 g of bioactive glass, place in 30 mL of ethanol, stir for 24 h to ensure homogenization, heat to 100 ° C, dry for 2 h, place in a sintering furnace, sinter at 700 ° C for 3 h, and cool to room temperature to obtain porous hydroxyapatite.

[0073] A2. Add 3.6 g of porous hydroxyapatite to 10 mL of zinc precursor solution, stir for 3 h, dry at 100 ° C for 1 h to remove most of the water, place in a muffle furnace and heat at 200 ° C for 1 h, heat to 650 ° C and keep for another 20 min, cool to room temperature, add 5.5 mL of zinc ammine complex solution, stir for 6 h, react at 90 ° C for 6 h, heat to 100 ° C, continue to react for 12 h, cool to room temperature, wash with deionized water 5 times, and dry in a 60 ° C oven for 20 min to obtain modified hydroxyapatite.

[0074] A3. Add 2.5 g of icariin to 10 mL of anhydrous ethanol, stir evenly, add 3.2 g of chitosan and 20 mL of 2% acetic acid solution, stir evenly, add 5.6 g of modified hydroxyapatite, react with stirring for 30 min, let stand at 4 ° C for 6 h, and freeze at -10 ° C for 3 h to obtain composite hydroxyapatite.

[0075] Comparative Example 1

[0076] The difference between this comparative example and Example 1 is that the modified hydroxyapatite is replaced by porous hydroxyapatite.

[0077] A1. Mix 3 g of hydroxyapatite and 1 g of bioactive glass, place in 30 mL of ethanol, stir for 24 h to ensure homogenization, heat to 100 ° C, dry for 2 h, place in a sintering furnace, sinter at 700 ° C for 3 h, and cool to room temperature to obtain porous hydroxyapatite.

[0078] A2. Add 2.5 g of icariin to 10 mL of anhydrous ethanol, stir evenly, add 3.2 g of chitosan and 20 mL of 2% acetic acid solution, stir evenly, add 5.6 g of porous hydroxyapatite, react with stirring for 30 min, let stand at 4 ° C for 6 h, and then freeze at -10 ° C for 3 h to obtain composite hydroxyapatite.

[0079] Comparative Example 2

[0080] The difference between this comparative example and Example 1 is that icariin and chitosan are not added.

[0081] A1. Mix 3 g of hydroxyapatite and 1 g of bioactive glass, place in 30 mL of ethanol, stir for 24 h to ensure homogenization, heat to 100 ° C, dry for 2 h, place in a sintering furnace, sinter at 700 ° C for 3 h, and cool to room temperature to obtain porous hydroxyapatite.

[0082] A2. Add 3.6 g of porous hydroxyapatite to 10 mL of zinc precursor solution, stir for 3 h, dry at 100 ° C for 1 h to remove most of the water, place in a muffle furnace and heat at 200 ° C for 1 h, heat to 650 ° C and keep for another 20 min, cool to room temperature, add 5.5 mL of zinc ammine complex solution, stir for 6 h, react at 90 ° C for 6 h, heat to 100 ° C, continue to react for 12 h, cool to room temperature, wash with deionized water 5 times, and dry in a 60 ° C oven for 20 min to obtain composite hydroxyapatite.

[0083] Example 2

[0084] The modified polylactic acid is specifically prepared by the following steps:

[0085] B1. Add 2.5 g of fish scale collagen and 3 g of chlorogenic acid to 30 mL of deionized water, stir evenly, add 0.2 g of 85% phosphoric acid, stir and react at 55°C for 30 min, filter, wash with deionized water 3 times, and freeze-dry at -10°C to obtain a composite antibacterial material.

[0086] B2. 6.5 g of L-lactide, 0.02 g of erythrobutene tetraol and 3.5 g of hydroxyethyl acrylate were mixed, stirred and reacted at 150°C for 10 min, cooled to room temperature, washed with deionized water three times, dried in an oven at 60°C for 10 min, added to 30 mL of ethanol, stirred evenly, 0.02 g of azobisisobutyronitrile and 1.6 g of 2-methacryloyloxyethyl phosphorylcholine were added, reacted at 60°C for 30 min, filtered, stirred at 85°C until the organic solvent evaporated, washed with deionized water three times, and dried in an oven at 60°C for 10 min to obtain a composite.

[0087] B3. Add 5g of the complex and 1.5g of the composite antibacterial material into 20mL of deionized water, stir evenly, add 0.2g of sodium hydroxide, stir in a 50°C water bath for 3h. After the reaction is completed, filter, wash with deionized water 3 times, and freeze-dry at -10°C to obtain modified polylactic acid.

[0088] Comparative Example 3

[0089] The difference between this comparative example and Example 2 is that fish scale collagen is not added.

[0090] B1. 6.5 g of lactide, 0.02 g of erythrobutene tetraol and 3.5 g of hydroxyethyl acrylate were mixed, stirred and reacted at 150°C for 10 min, cooled to room temperature, washed with deionized water three times, dried in an oven at 60°C for 10 min, added to 30 mL of ethanol, stirred evenly, 0.02 g of azobisisobutyronitrile and 1.6 g of 2-methacryloyloxyethyl phosphorylcholine were added, reacted at 60°C for 30 min, filtered, stirred at 85°C until the organic solvent evaporated, washed with deionized water three times, and dried in an oven at 60°C for 10 min to obtain a composite.

[0091] B3. Add 5 g of the complex and 1.5 g of chlorogenic acid into 20 mL of deionized water, stir evenly, add 0.2 g of sodium hydroxide, stir in a 50 ° C water bath for 3 h. After the reaction is completed, filter, wash with deionized water 3 times, and freeze-dry at -10 ° C to obtain modified polylactic acid.

[0092] Comparative Example 4

[0093] The difference between this comparative example and Example 2 is that the composite is replaced with commercially available polylactic acid.

[0094] B1. Add 2.5 g of fish scale collagen and 3 g of chlorogenic acid to 30 mL of deionized water, stir evenly, add 0.2 g of 85% phosphoric acid, stir and react at 55°C for 30 min, filter, wash with deionized water 3 times, and freeze-dry at -10°C to obtain a composite antibacterial material.

[0095] B3. Add 5 g of commercially available polylactic acid and 1.5 g of composite antibacterial material into 20 mL of deionized water, stir evenly, add 0.2 g of sodium hydroxide, stir in a 50°C water bath for 3 h. After the reaction is completed, filter, wash with deionized water 3 times, and freeze-dry at -10°C to obtain modified polylactic acid.

[0096] Example 3

[0097] The method for preparing an absorbable scaffold for human alveolar bone reconstruction comprises the following steps:

[0098] S1. Mix 0.8g α-tricalcium phosphate, 0.6g modified polylactic acid, 0.1g composite hydroxyapatite, and 0.02g nano magnesium oxide, and after ball milling three times, separate the ball mill and the material through a 6mm sieve to obtain a ball milled mixture. The ball milling conditions are as follows: the ratio of 3mm and 5mm magnesium oxide balls is 4:1, the ball milling speed is 300r / min, and the ball milling process is forward for 30min, stopped for 10min, and reversed for 30min.

[0099] S2. The ball-milled mixture was melt-blended at 155°C for 5 minutes at a speed of 65 rpm, and then tableted, cooled to room temperature, and modeled and printed using CAD / CAM technology to obtain an absorbable stent. The tableting pressure was 7 tons, and the tableting holding time was 1 minute; the CAD / CAM technology model was designed with a line diameter of 500um and a pore diameter of 250um; the printing parameters were: layer height 0.1mm, filling rate 100%, printing rate 30mm / s, printing temperature 185°C, platform temperature 45°C, and printing nozzle 0.1mm.

[0100] Example 4

[0101] The method for preparing an absorbable scaffold for human alveolar bone reconstruction comprises the following steps:

[0102] S1. Mix 1g α-tricalcium phosphate, 0.7g modified polylactic acid, 0.15g composite hydroxyapatite, and 0.03g nano magnesium oxide, and after ball milling three times, separate the ball mill and the material through a 6mm sieve to obtain a ball milled mixture. The ball milling conditions are as follows: the ratio of 3mm and 5mm magnesium oxide balls is 4:1, the ball milling speed is 300r / min, and the ball milling process is forward for 30min, stopped for 10min, and reversed for 30min.

[0103] S2. The ball-milled mixture was melt-blended at 155°C for 5 minutes at a speed of 65 rpm, and then tableted, cooled to room temperature, and modeled and printed using CAD / CAM technology to obtain an absorbable stent. The tableting pressure was 7 tons, and the tableting holding time was 1 minute; the CAD / CAM technology model was designed with a line diameter of 500um and a pore diameter of 250um; the printing parameters were: layer height 0.1mm, filling rate 100%, printing rate 30mm / s, printing temperature 185°C, platform temperature 45°C, and printing nozzle 0.1mm.

[0104] Example 5

[0105] The method for preparing an absorbable scaffold for human alveolar bone reconstruction comprises the following steps:

[0106] S1. 1.2g α-tricalcium phosphate, 0.8g modified polylactic acid, 0.2g composite hydroxyapatite, and 0.04g nano magnesium oxide were mixed, ball-milled three times, and separated from the ball mill and the material through a 6mm sieve to obtain a ball-milled mixture. The ball-milling conditions were as follows: the ratio of 3mm and 5mm magnesium oxide balls was 4:1, the ball-milling speed was 300r / min, and the ball-milling process was forward for 30min, stopped for 10min, and reversed for 30min.

[0107] S2. The ball-milled mixture was melt-blended at 155°C for 5 minutes at a speed of 65 rpm, and then tableted, cooled to room temperature, and modeled and printed using CAD / CAM technology to obtain an absorbable stent. The tableting pressure was 7 tons, and the tableting holding time was 1 minute; the CAD / CAM technology model was designed with a line diameter of 500um and a pore diameter of 250um; the printing parameters were: layer height 0.1mm, filling rate 100%, printing rate 30mm / s, printing temperature 185°C, platform temperature 45°C, and printing nozzle 0.1mm.

[0108] Comparative Example 5

[0109] The difference between this comparative example and Example 4 is that the composite hydroxyapatite is replaced by the material prepared in Comparative Example 1.

[0110] Comparative Example 6

[0111] The difference between this comparative example and Example 4 is that the composite hydroxyapatite is replaced by the material prepared in Comparative Example 2.

[0112] Comparative Example 7

[0113] The difference between this comparative example and Example 4 is that the modified polylactic acid is replaced by the substance prepared in Comparative Example 3.

[0114] Comparative Example 8

[0115] The difference between this comparative example and Example 4 is that the modified polylactic acid is replaced by the substance prepared in Comparative Example 4.

[0116] The performance of the absorbable stents prepared in Examples 3-5 and Comparative Examples 5-8 was tested.

[0117] The absorbable scaffold prepared as above is used in the reconstruction of human alveolar bone.

[0118] Mechanical property testing of absorbable stents: At 25°C, the absorbable stents prepared above were compressed using an electronic material universal testing machine with a 5KN load sensor at a speed of 1 mm / min until the sample yielded, and the yield strength and elastic modulus of the absorbable stent were recorded.

[0119] Antibacterial test: According to ASTM G21-15, the antibacterial properties of the absorbable stent prepared above were evaluated using Escherichia coli and Staphylococcus aureus.

[0120] Absorbable scaffold bone cell proliferation experiment: According to the absorbable scaffold cell proliferation experimental method in "Pan Wushuang. Preparation of modified fish scale collagen flocculant and its application in pear juice clarification [D]. Sichuan Agricultural University, 2023.", the osteoblast counting analysis and statistical analysis were performed. The test results are shown in Table 1 below.

[0121] surface@

[0122]

[0123] It can be seen from the data in Table 1 that in Comparative Example 5, the composite hydroxyapatite prepared by replacing the modified hydroxyapatite with porous hydroxyapatite and forming an absorbable scaffold with modified polylactic acid has decreased mechanical strength, osteoblast proliferation rate and antibacterial properties. This may be because the zinc oxide nanowires serve as the supporting skeleton of the porous hydroxyapatite, improving the mechanical strength of the porous hydroxyapatite; and the zinc oxide nanowires refine the pore size of the porous hydroxyapatite, increase the loading amount and adsorption capacity of icariin, and improve the sustained release time. The zinc nanowires have good antibacterial properties; in Comparative Example 6, the composite hydroxyapatite prepared without adding icariin and chitosan was combined with modified polylactic acid to form an absorbable scaffold, and its mechanical strength and osteoblast proliferation rate decreased. This may be because icariin can promote the proliferation of osteoblasts, and chitosan forms a cross-linked network structure on the surface of the composite hydroxyapatite, which adsorbs icariin, increases the sustained release time of icariin, improves the bone induction activity and the regeneration rate of bone tissue at the implantation site, thereby promoting the repair of alveolar bone. Composite effect; Comparative Example 7 is prepared by polylactic acid modified without adding fish scale collagen, and is processed into an absorbable scaffold, and its mechanical strength, bone cell proliferation rate and antibacterial properties are reduced. This may be because chlorogenic acid is grafted on fish scale collagen to avoid the easy migration and precipitation of chlorogenic acid in the polylactic acid absorbable scaffold, and fish scale collagen has a proliferation and differentiation-promoting effect on bone cells, and has good osteogenesis. Fish scale collagen can complex with calcium ions in composite hydroxyapatite to enhance the spatial structure of the porous absorbable scaffold and enhance the mechanical strength of the absorbable scaffold; Comparative Example 8 replaces the composite with commercially available polylactic acid modified polylactic acid and is processed into an absorbable scaffold, and its mechanical strength and bone cell proliferation rate are reduced. This may be because the molecular weight of polylactic acid carries a phosphorylcholine group, which enhances the anti-protein adsorption ability and is beneficial to the regeneration of alveolar bone. The ester group contained in the polylactic acid carrying the phosphorylcholine group is chemically bonded with the composite antibacterial material, and is cross-linked to form a porous network, thereby enhancing the mechanical strength of the absorbable scaffold matrix polylactic acid.

[0124] The data in Table 1 show that the absorbable scaffolds prepared in Examples 3-5 not only have good alveolar bone repair function and mechanical strength, but also have good antibacterial and anti-inflammatory properties. α-tricalcium phosphate, modified polylactic acid, composite hydroxyapatite, and nano-magnesium oxide are mixed, ball-milled three times, and the ball milling and materials are separated through a sieve to obtain a ball-milled mixture; the ball-milled mixture is melt-blended, and then tabletted, cooled to room temperature, and the model is cut and printed using CAD / CAM technology to obtain an absorbable scaffold that meets the test performance requirements, while the absorbable scaffolds prepared in Comparative Examples 5-8 do not meet the performance requirements, indicating that the absorbable scaffolds prepared by the present invention not only have good alveolar bone repair function and mechanical strength, but also have good antibacterial and anti-inflammatory properties.

[0125] In the description of the specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0126] The above contents are merely examples and explanations of the present invention. Those skilled in the art may make various modifications or additions to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the invention or exceed the scope defined by the claims, they shall all fall within the protection scope of the present invention.

Claims

1. A method for preparing an absorbable scaffold for human alveolar bone reconstruction, characterized in that: The following steps are involved: S1. α-tricalcium phosphate, modified polylactic acid, composite hydroxyapatite and nano-magnesium oxide are mixed and ball-milled three times, and the ball-milled and material are separated through a sieve to obtain a ball-milled mixture; The composite hydroxyapatite is prepared by mixing modified hydroxyapatite, icariin and chitosan and stirring them for reaction; The modified hydroxyapatite is prepared by mixing hydroxyapatite and bioactive glass, sintering them, and then mixing them with a zinc precursor solution and a zinc ammine complex solution, and heating them for reaction; The modified polylactic acid is prepared by copolymerizing lactide with hydroxyethyl acrylate and 2-methacryloyloxyethyl phosphorylcholine, and then mixing with a composite antibacterial material; The composite antibacterial material is prepared by reacting fish scale collagen with chlorogenic acid; S2. The ball-milled mixture is melt-blended, and then tableted, cooled to room temperature, and modeled and printed using CAD / CAM technology to obtain an absorbable scaffold.

2. The method for preparing an absorbable scaffold for human alveolar bone reconstruction according to claim 1, characterized in that: The mass ratio of the modified polylactic acid and the composite hydroxyapatite is (0.5-0.9):(0.1-0.2)。 3. The method for preparing an absorbable scaffold for human alveolar bone reconstruction according to claim 1, characterized in that: The zinc precursor solution is prepared by mixing zinc acetate, polyethylene glycol 600 and deionized water in a dosage ratio of (3.5-4) g:(10-20) g:(40-50) mL; the zinc ammonia complex solution is prepared by mixing zinc nitrate and ammonia water in a dosage ratio of (1.6-2) g:(10-12) mL.

4. The method for preparing an absorbable scaffold for human alveolar bone reconstruction according to claim 1, characterized in that: The mass ratio of the hydroxyapatite to the bioactive glass is (2-4):(0.5-1.5).

5. The method for preparing an absorbable scaffold for human alveolar bone reconstruction according to claim 1, characterized in that: The lactide is selected from L-lactide or D-lactide.

6. The method for preparing an absorbable scaffold for human alveolar bone reconstruction according to claim 1, characterized in that: The particle size of the nano magnesium oxide is 40-60nm; the ball milling conditions are as follows: the ratio of the number of 3mm and 5mm magnesium oxide balls is 4:1, the ball milling speed is 280-320r / min, the ball milling process is forward for 25-35min, the intermediate stop is 8-12min, and the reverse rotation is 25-35min.

7. The method for preparing an absorbable scaffold for human alveolar bone reconstruction according to claim 1, characterized in that: The printing parameters are as follows: layer height 0.1 mm, filling rate 100%, printing speed 30 mm / s, printing temperature 185° C., platform temperature 45° C., and printing nozzle 0.1 mm.

8. The method for preparing an absorbable scaffold for human alveolar bone reconstruction according to claim 1, characterized in that: The CAD / CAM technical model designs a wire diameter of 450-550um and an aperture of 200-300um.

9. The method for preparing an absorbable scaffold for human alveolar bone reconstruction according to claim 1, characterized in that: The tableting pressure is 6-8 tons, and the tableting holding time is 0.5-1.5 minutes; the melt blending temperature is 150-160° C., the melt blending time is 2-7 minutes, and the rotation speed is 60-70 rpm.

10. Use of the absorbable scaffold prepared according to the preparation method according to any one of claims 1 to 9 in human alveolar bone reconstruction.

Citation Information

Cited By

  • Biomedical scaffold, preparation method therefor, use method therefor, and use thereof

    WO2026060559A1